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Abstract
This study describes predictors of pneumococcal nasopharyngeal carriage and density in
Fiji. We used data from four annual (2012–2015) cross-sectional surveys, pre- and post-
introduction of ten-valent pneumococcal conjugate vaccine (PCV10) in October 2012.
Infants (5–8 weeks), toddlers (12–23 months), children (2–6 years), and their caregivers
participated. Pneumococci were detected and quantified using lytA qPCR, with molecular
serotyping by microarray. Logistic and quantile regression were used to determine predic-
tors of pneumococcal carriage and density, respectively. There were 8,109 participants.
Pneumococcal carriage was negatively associated with years post-PCV10 introduction
(global P<0.001), and positively associated with indigenous iTaukei ethnicity (aOR 2.74
[95% CI 2.17–3.45] P<0.001); young age (infant, toddler, and child compared with caregiver
participant groups) (global P<0.001); urban residence (aOR 1.45 [95% CI 1.30–2.57]
P<0.001); living with�2 children <5 years of age (aOR 1.42 [95% CI 1.27–1.59] P<0.001);
low family income (aOR 1.44 [95% CI 1.28–1.62] P<0.001); and upper respiratory tract
infection (URTI) symptoms (aOR 1.77 [95% CI 1.57–2.01] P<0.001). Predictors were similar
for PCV10 and non-PCV10 carriage, except PCV10 carriage was negatively associated
with PCV10 vaccination (0.58 [95% CI 0.41–0.82] P = 0.002) and positively associated with
exposure to household cigarette smoke (aOR 1.21 [95% CI 1.02–1.43] P = 0.031), while
there was no association between years post-PCV10 introduction and non-PCV10 carriage.
Pneumococcal density was positively associated with URTI symptoms (adjusted median dif-
ference 0.28 [95% CI 0.16, 0.40] P<0.001) and toddler and child, compared with caregiver,
participant groups (global P = 0.008). Predictors were similar for PCV10 and non-PCV10
density, except infant, toddler, and child participant groups were not associated with PCV10
density. PCV10 introduction was associated with reduced the odds of overall and PCV10
pneumococcal carriage in Fiji. However, after adjustment iTaukei ethnicity was positively
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Introduction
Pneumococcal disease is a leading cause of childhood morbidity and mortality worldwide [1].
Pneumococcal disease is preceded by pneumococcal nasopharyngeal carriage, and the severity
of pneumococcal pneumonia is associated with bacterial load (density) of pneumococci in the
nasopharynx [2, 3]. Public health interventions to prevent pneumococcal disease can be
improved by identifying the factors associated with pneumococcal carriage. Determining fac-
tors associated with higher pneumococcal carriage density could aid estimation of pneumo-
coccal pneumonia prevalence in childhood pneumonia studies [2].
In low- and middle-income countries, risk factors for pneumococcal nasopharyngeal car-
riage vary [4–8] and few studies have investigated factors associated with the density of pneu-
mococcal carriage in healthy populations [2, 9–11]. Common factors positively associated with
pneumococcal carriage in low- and middle-income countries include indigenous ethnicity,
passive smoking; co-colonisation with Haemophilus influenzae, childcare attendance, poverty,
acute respiratory infection, living with young children, and being under five years old [4, 8,
12]. In studies from low- and middle-income countries, higher pneumococcal density has
been positively associated with the symptoms of upper respiratory tract infection, presence of
a febrile acute respiratory infection in children [13], rainy season, severe pneumonia, viral co-
infection, radiologically confirmed pneumococcal pneumonia, and encapsulated serotypes
(compared with non-encapsulated serotypes) [2, 9–11, 13–16].
Pneumococcal conjugate vaccines (PCV) reduce vaccine-type carriage and disease [17, 18].
However, serotype replacement with non-vaccine-type carriage occurs following the introduc-
tion of PCV which can result in non-vaccine-type disease [19, 20]. In the post-PCV era, it is
largely unknown what the impact of PCV is on the risk factors for pneumococcal carriage and
density in low- and middle-income countries in the Asia-Pacific region.
In 2012, Fiji introduced the ten-valent PCV (PCV10). Six years before PCV10 was intro-
duced, factors associated with pneumococcal carriage in healthy 3–13 month old Fijians
included indigenous iTaukei (iTaukei) ethnicity and having symptoms of an upper respiratory
tract infection (URTI)[4]. iTaukei ethnicity was also associated with higher median pneumo-
coccal density among 17 month old Fijians [21]. Fiji provides an opportunity to investigate fac-
tors associated with pneumococcal carriage and density in the post-PCV10, in a tropical,
upper middle-income setting. As part of a PCV10 impact evaluation on pneumococcal car-
riage, we previously reported that the prevalence of vaccine-type carriage declined in both
iTaukei and Fijians of Indian Descent (FID) three years after the introduction of PCV10, but
carriage of non-vaccine-type carriage increased in iTaukei infants and toddlers [22]. The aim
of this study is to determine the factors associated with carriage and density of pneumococci
(overall, vaccine-type, and non-vaccine-type) in Fiji up to three years following PCV10
introduction.
Materials and methods
Setting
The majority of the Fijian population (81%) lives on Viti Levu, the bigger of Fiji’s two main
islands. Greater than half (56.8%) of the population are iTaukei and 37.8% are FID. This study
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was conducted in Suva, and the surrounding areas, where over one-third of the population
lives [23]. PCV10 was introduced nationally in October 2012 to be administered at 6, 10, and
14 weeks of age, with no catch-up campaign. The national coverage of the third dose of PCV10
one, two, and three years post-introduction was 84.9%, 84.9%, and 89.0%, respectively [24–
26].
Cross-sectional carriage studies
The design and methods for these cross-sectional studies have been described elsewhere [22].
Briefly, four annual cross-sectional carriage surveys were undertaken: one pre-PCV10 (2012),
and then annually thereafter (2013–2015). Purposive quota sampling achieved a sample pro-
portionate to the national iTaukei: FID (3:2) and rural: urban (1:1) ratios [4, 23, 27]. Each year,
approximately 500 participants were recruited into each of the following four groups: infants
5–8 weeks (infants), toddlers 12–23 months (toddlers), children 2–6 years (children), and their
parents/guardians (caregivers). Age groups were selected in order to best answer the primary
research question regarding impact of PCV10 on pneumococcal carriage prevalence in Fiji,
and as described previously, were based on those most likely to benefit from direct and indirect
effects of PCV10; those likely to have the highest pneumococcal carriage prevalence; those age-
eligible for PCV10 vaccination; and those most likely to transmit or be in contact with trans-
mitters of pneumococci [22]. This analysis used the same study population.
Participants were recruited from two health centres in the Greater Suva area, and from sur-
rounding communities. Eligibility criteria included age or being a caregiver, and for non-
infant participants, that they had lived in the area for at least three months. Those with an axil-
lary temperature�37.0˚C were excluded. For the pre-PCV10 survey, any receipt of PCV10
was an exclusion criterion for all participant groups. For subsequent surveys, only infants who
had ever received PCV10 were excluded.
Study staff interviewed caregivers and recorded individual level participant characteristics
on data collection forms. Variables collected included: self-reported ethnicity, sex, residential
location, antibiotic use in the fortnight preceding the survey, exposure to household cigarette
smoke, coryza, symptoms of allergic rhinitis, cough, ear discharge, number of children less
than five years in the household, and weekly family income. Caregivers reported their own,
and their participating child’s or children’s ethnicity, according to options defined by the
investigator (iTaukei, FID, or other) and recognized by Fijian population[23]. PCV10 vaccina-
tion status for infants and children was obtained from written records. As PCV10 was unavail-
able privately, caregivers were assumed to be PCV10 unvaccinated. A binary variable for
symptoms of URTI was derived from the presence of one or more of the following: coryza,
allergic rhinitis, cough, or ear discharge. A binary variable for low family income was derived,
defined as family income on / above or below the basic needs poverty line (<FJ$175 per week)
[28].
Trained study nurses collected nasopharyngeal samples using flocked nylon swabs
(COPAN FLOQSwabsTM), which were transported and stored according to standard methods,
as described previously [22, 29]. Microbiological analyses were undertaken at the Murdoch
Children’s Research Institute in Melbourne, Australia as described previously [22]. In brief,
pneumococci were detected using real-time quantitative-polymerase chain reaction targeting
the lytA gene, with molecular serotyping by microarray [29–31]. Laboratory staff were blinded
to participant characteristic data. Detection of any pneumococci in swab samples, including
non-encapsulated lineages, was defined as overall pneumococcal carriage. Detection of sero-
types included in PCV10 (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) was defined as
PCV10 carriage, and detection of serotypes not included in PCV10, including non-
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Table 1. Characteristics of participants in four annual cross-sectional community nasopharyngeal carriage sur-
veys, 2012–2015, Fiji (n = 8,109 a).
Characteristics Summary statistic
PCV10 vaccinatedb, n (%) 1105 (13.6)
Survey year, n (%)
Pre-PCV10 (2012) 2025 (25.0)
1 year post-PCV10 (2013) 2042 (25.2)
2 years post-PCV10 (2014) 2022 (24.9)
3 years post PCV10 (2015) 2020 (24.9)
Ethnicity, n (%)
Fijian of Indian Descent 3236 (39.9)
iTaukei 4835 (59.6)
Other 38 (0.5)
Participant group, n (%)
Infants (5–8 weeks) 2006 (24.7)
Toddlers (12–23 months) 2004 (24.7)
Children (2–6 years) 2052 (25.3)
Caregivers 2047 (25.3)
Residential location, n (%)
Rural 3944 (48.6)
Urban 4165 (51.4)
Female sex, n (%) 4683 (57.8)
Two or more children under five years in the household, n (%) n = 8106
4004 (49.4)
Low family incomec, n (%) n = 7831
4599 (58.7)
Symptoms of URTI, n (%) 2092 (25.8)
Exposure to household cigarette smoke, n (%) 4353 (53.7)
Antibiotic use in past fortnight, n (%) n = 8105
357 (4.4)
Pneumococcal carriage, n / N (%)
Overalld n = 8061
2456 (30.5)
PCV10 serotypese n = 8000
713 (8.9)
Non-PCV10 serotypesf n = 8000
1915 (23.9)
Non-encapsulated pneumococcig n = 8000
390 (4.9)
Pneumococcal densityh, n, median log10 GE/ml (IQR)
Overall 2455, 5.0 (4.2–5.7)
PCV10 serotypes 713, 4.9 (4.1–5.6)
Non-PCV10 serotypes 1915, 4.9 (4.1–5.7)
Non-encapsulated pneumococci 390, 4.3 (3.7–4.9)
Abbreviations: PCV10, ten-valent pneumococcal conjugate vaccine; URTI, upper respiratory tract infection; IQR,
interquartile range.
a Unless otherwise specified
b Two doses of PCV10 given before the age of 12 months, or one or more doses of PCV10 given at or after 12 months
of age[35]
c Weekly family income below the basic needs poverty line (<FJ$175 per week)[28]
d Any pneumococci, including non-encapsulated lineages
e Pneumococcal serotypes included in PCV10 (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F)
f Pneumococcal serotypes not included in PCV10, including non-encapsulated lineages
g Includes carriage of any of the following non-encapsulated lineages: NT, NT1, NT2, NT2/NT3b, NT3a, NT3b,
NT4a, NT4b
h Only includes participants who were carriers of indicated pneumococcal types
https://doi.org/10.1371/journal.pone.0231041.t001
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encapsulated lineages, was defined as non-PCV10 carriage. Detection by microarray of a
PCV10 serotype and a non-PCV10 serotype from the same swab sample was recorded as posi-
tive for both PCV10 and non-PCV10 serotype carriage [22]. Any detection of a serotype by
microarray was considered positive, regardless of relative abundance [22]. Non-encapsulated
lineages were classified based upon previously described genetic variants [32]. We determined
pneumococcal density only for pneumococcal positive samples, and reported it in genome
equivalents per ml (GE / ml). Participant characteristic data were double entered, and vali-
dated, in an EpiData 3.1 database [33]. Microbiological outcome data were entered into Micro-
soft Excel (Excel 2013) and merged with characteristic data in Stata 15.1 [34].
Statistical analyses
Participant characteristics were summarised using counts and percentages. We built logistic
and quantile regression models to investigate the factors associated with pneumococcal car-
riage and density, respectively. Empirical univariable results (p<0.2) and a priori selection
informed variable choice for multivariable models. Factors assessed empirically included resi-
dential location, participant sex, two or more children under five years living in the household,
low family income, exposure to household cigarette smoke, and recent antibiotic use. Variables
selected a priori included PCV10 vaccination, survey year, ethnicity, participant group, and
URTI symptoms [4, 14]. Interaction terms for ethnicity with PCV10 vaccination status, and
with survey year, were assessed to account for the potential differential effect of PCV10 vacci-
nation, or number of years post-PCV10 introduction, on pneumococcal carriage and density
by ethnicity. We also assessed potential interaction between ethnicity and other socio-demo-
graphic factors in the models. Interaction terms were included as indicated, with significance
level set at P<0.05. Estimates of the association of participant characteristics with carriage and
density were reported as odds ratios and differences in medians, respectively, with 95% confi-
dence intervals (95% CI) and P-values. Pneumococcal density data were log10 transformed
prior to analyses, and analyses of pneumococcal density were restricted to pneumococcal carri-
ers. Only 14/38 participants who identified as “other” ethnicity had pneumococcal positive
samples, so were excluded from inferential analyses. Merged data were cleaned and analysed
in Stata 15.1 [34].
Ethics statement
This study was carried out in accordance with the protocols approved by the Fijian National
Health Research and Ethics Review Committee (201228), and The University of Melbourne
Health Sciences Human Ethics Sub-Committee (1238212). Study staff discussed the study with
caregivers, and written informed consent was completed prior to any study procedures. Partic-
ipants were not offered any incentive to participate.
Results
Participant characteristics
There were 8,109 participants, with characteristics shown in Table 1. The overall vaccination
rate of 13.6% reflects the pooled participant group, most (85.8%) of which were not age-eligible
to receive PCV10. Similar numbers of people participated per survey year and by participant
group [22]. Few had used antibiotics in the preceding two weeks. Forty-eight participant swab
samples were excluded from microbiological analysis due to insufficient volume, sample loss,
or labelling errors. A further 61 pneumococcal positive samples were excluded from serotyping
due to biological reasons or technical issues. Of the 8,061 participants for whom swab sample
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results were available, 30.5% tested positive for pneumococci. Among the 8,000 serotyped sam-
ples, PCV10 carriage was uncommon (8.9%), and 23.9% of participants carried non-PCV10
pneumococci. Carriage of non-encapsulated pneumococci was rare (390 / 8,000, 4.9%). Den-
sity data was unavailable for one pneumococcal carrier. Overall carriage median density was
5.0 log10 GE/ml (4.2–5.7), while those for PCV10, non-PCV10 carriage, and non-encapsulated
lineages were 4.9 log10 GE/ml (4.1–5.6), 4.9 log10 GE/ml (4.1–5.7), and 4.3 log10 GE/ml (3.7–
4.9), respectively [22].
Factors associated with overall carriage
ITaukei ethnicity, young age (infant, toddler, and child participant groups vs caregivers),
urban residence, living with two or more children under five years, low family income, and
URTI symptoms were positively associated with overall carriage (Table 2). Survey year was
negatively associated with overall carriage. There was evidence of protection from PCV10 vac-
cination against overall carriage, however the confidence interval crossed the null value. There
was evidence of an interaction between survey year and ethnicity (global P<0.001), but no evi-
dence of an interaction between PCV10 vaccination status and ethnicity (global P = 0.880).
Factors associated with PCV10 carriage
iTaukei ethnicity, young age (infant, toddler, and child participant groups), urban residence,
living with two or more children under five years, low family income, symptoms of URTI, and
exposure to household cigarette smoke were positively associated with PCV10 carriage
(Table 3). PCV10 vaccination and survey year were negatively associated with PCV10 carriage.
There was no evidence of an interaction between PCV10 vaccination status (P = 0.902) or sur-
vey year (P = 0.171) and ethnicity with regard to PCV10 carriage.
Factors associated with non-PCV10 carriage
iTaukei ethnicity, young age (infant, toddler, and child participant groups), urban residence,
living with two or more children younger than five years, low family income, and URTI symp-
toms were positively associated with non-PCV10 carriage (S1 Table). As with overall carriage,
there was evidence of an interaction between survey year and ethnicity, as the two ethnic
groups had differential odds of non-PCV10 carriage (P<0.001), but no evidence of interaction
between PCV10 vaccination status and ethnicity (P = 0.856).
Factors associated with overall pneumococcal density
Toddler and child participant groups, and symptoms of URTI were positively associated with
density of overall pneumococcal carriage (Table 4). There was evidence of an association
between iTaukei ethnicity and overall pneumococcal density, however the confidence interval
included the null value. Although the adjusted median difference in overall pneumococcal car-
riage density increased in the first two years after the introduction of PCV10, this was not sus-
tained into the third year (Table 4). There was no indication of an interaction between PCV10
vaccination status (P = 0.864) or survey year (P = 0.347) with ethnicity.
Factors associated with PCV10 pneumococcal density
Symptoms of URTI were positively associated with median density of PCV10 carriage (S2
Table). Although there was an initial increase in the adjusted median difference in PCV10 car-
riage density in the first year after PCV10 introduction, it was not sustained through the sec-
ond and third year post-PCV10 introduction (S2 Table). There was no indication of an
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Table 2. Unadjusted and adjusted odds ratios of overall pneumococcal carriage in association with participant characteristics in four cross-sectional carriage sur-
veys pre-PCV10 (2012) and annually thereafter (2013–2015) in Fiji (n = 8,023).
Exposure Overall carriagea n/N (%) Unadjusted odds ratio (95% CI) P-value Adjusted odds ratio (95% CI) P-value
PCV10 vaccination status <0.001 0.065
Not vaccinated 2027 / 6931 (29.3) ref ref
Vaccinatedb 415 / 1092 (38.0) 1.48 (1.30–1.69) 0.82 (0.66–1.01)
Survey year <0.001 <0.001
Pre-PCV10 (2012) 708 / 2001 (35.4) ref ref
1 year post-PCV10 (2013) 655 / 2033 (32.2) 0.87 (0.76–0.99) 0.67 (0.51–0.88)
2 years post-PCV10 (2014) 433 / 1997 (21.7) 0.51 (0.44–0.58) 0.49 (0.36–0.66)
3 years post PCV10 (2015) 646 / 1992 (32.4) 0.88 (0.77–1.00) 0.62 (0.46–0.83)
Ethnicity <0.001 <0.001
Fijian of Indian Descent 496 / 3218 (15.4) ref ref
iTaukei 1946 / 4805 (40.5) 3.74 (3.34–4.18) 2.74 (2.17–3.45)
Participant group <0.001 <0.001
Caregivers 193 / 2035 (9.5) ref Ref
Infants (5–8 weeks) 516 / 1974 (26.1) 3.38 (2.82–4.04) 4.15 (3.40–5.06)
Toddlers (12–23 months) 845 / 1986 (42.6) 7.07 (5.95–8.40) 8.88 (7.13–11.07)
Children (2–6 years) 888 / 2028 (43.8) 7.43 (6.26–8.83) 8.48 (6.99–10.29)
Residential location <0.001 <0.001
Rural 1070 / 3911 (27.4) ref ref
Urban 1372 / 4112 (33.4) 1.33 (1.21–1.46) 1.45 (1.30–2.57)
Participant sex <0.001 0.300
Male 1167 / 3385 (34.5) ref ref
Female 1275 / 4638 (27.5) 0.72 (0.65–0.79) 1.06 (0.95–1.19)
Number of children < 5 years
living in the householdc
<0.001 <0.001
Less than two 955/4067 (23.5) ref ref
Two or more 1487 / 3953 (37.6) 1.96 (1.78–2.16) 1.42 (1.27–1.59)
Family income leveld <0.001 <0.001
Not low 801 / 3193 (25.1) ref ref
Low 1523 / 4558 (33.4) 1.50 (1.35–1.66) 1.44 (1.28–1.62)
Symptoms of URTI <0.001 <0.001
Not present 1529 / 5955 (25.7) ref ref
Present 913 / 2068 (44.2) 2.29 (2.06–2.54) 1.77 (1.57–2.01)
Household cigarette smoke 0.105 0.555
No exposure 1099 / 3729 (29.5) ref ref
Exposure 1343 / 4303 (31.2) 1.08 (0.98–1.19) 0.97 (0.87–1.08)
Antibiotic use in previous
fortnighte
0.350
Not used 2325 / 7667 (30.3) ref
Used 115 / 352 (32.7) 1.11 (0.89–1.40)
Abbreviations: CI, confidence interval; PCV10, ten-valent pneumococcal conjugate vaccine; URTI, upper respiratory tract infection.
a Any pneumococci, including non-encapsulated lineages
b Two doses of PCV10 given before the age of 12 months, or one or more doses of PCV10 given at or after 12 months of age[35]
c Data on number of children under five years living in the household were missing for three participants, of whom none were pneumococcal carriers
d Weekly family income below the basic needs poverty line (<FJ$175 per week)[28]; data on family income were missing for 272 participants, of whom 118 were
pneumococcal carriers
e Data on antibiotics use were missing for four participants, of whom two were pneumococcal carriers.
https://doi.org/10.1371/journal.pone.0231041.t002
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Table 3. Unadjusted and adjusted odds ratios of PCV10 pneumococcal carriage in association with participant characteristics in four cross-sectional carriage sur-
veys pre-PCV10 (2012) and annually thereafter (2013–2015) in Fiji (n = 7,962).
Exposure PCV10 carriagea n / N (%) Unadjusted odds ratio (95% CI) P-value Adjusted odds ratio (95% CI) P-value
PCV10 vaccination status 0.043 0.002
Not vaccinated 629 / 6875 (9.2) ref ref
Vaccinatedb 79 / 1087 (7.3) 0.78 (0.61–0.99) 0.58 (0.41–0.82)
Survey year <0.001 <0.001
Pre-PCV10 (2012) 275 / 1975 (13.9) ref ref
1 year post-PCV10 (2013) 216 / 2022 (10.7) 0.74 (0.61–0.89) 0.74 (0.60–0.91)
2 years post-PCV10 (2014) 102 / 1987 (5.13) 0.33 (0.26–0.42) 0.40 (0.30–0.53)
3 years post PCV10 (2015) 115 / 1978 (5.8) 0.38 (0.30–0.48) 0.46 (0.35–0.61)
Ethnicity <0.001 <0.001
Fijian of Indian Descent 147 / 3206 (4.6) ref ref
iTaukei 561 / 4756 (11.8) 2.78 (2.31–3.36) 2.70 (2.21–3.30)
Participant group <0.001 <0.001
Caregivers 41 / 2029 (2.0) ref ref
Infants (5–8 weeks) 121 / 1946 (6.2) 3.21 (2.24–4.61) 3.60 (2.45–5.30)
Toddlers (12–23 months) 277 / 1972 (14.1) 7.92 (5.67–11.07) 9.76 (6.67–14.37)
Children (2–6 years) 269 / 2015 (13.4) 7.47 (5.34–10.44) 7.65 (5.32–11.00)
Residential location 0.001 0.001
Rural 304 / 3880 (7.8) ref ref
Urban 404 / 4082 (9.9) 1.29 (1.11–1.51) 1.34 (1.13–1.58)
Participant sex <0.001 0.772
Male 352 / 3358 (10.5) ref ref
Female 356 / 4604 (7.7) 0.72 (0.61–0.84) 0.98 (0.82–1.16)
Number of children < 5 years
living in the householdc
<0.001 0.040
Less than two 283 / 4035 (7.0) ref ref
Two or more 425 / 3924 (10.8) 1.61 (1.38–1.88) 1.20 (1.01–1.43)
Family income leveld <0.001 0.004
Not low 207 / 3175 (6.5) ref ref
Low 463 / 4518 (10.3) 1.64 (1.38–1.94) 1.31 (1.09–1.57)
Symptoms of URTI <0.001 <0.001
Not present 435 / 5903 (7.4) ref ref
Present 273 / 2059 (13.3) 1.92 (1.64–2.26) 1.42 (1.19–1.70)
Household cigarette smoke <0.001 0.031
No exposure 283 / 3689 (7.7) ref ref
Exposure 425 / 4273 (10.0) 1.33 (1.14–1.56) 1.21 (1.02–1.43)
Antibiotic use in previous
fortnighte
0.012 0.367
Not used 663 / 7610 (8.7) ref ref
Used 44 / 348 (12.6) 1.52 (1.09–2.10) 0.84 (0.58–1.22)
Abbreviations: CI, confidence interval; PCV10, ten-valent pneumococcal conjugate vaccine; URTI, upper respiratory tract infection.
a Pneumococcal serotypes included in PCV10 (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F)
b Two doses of PCV10 given before the age of 12 months, or one or more doses of PCV10 given at or after 12 months of age [35]
c Data on number of children under five years living in the household were missing for three participants, of whom none were PCV10 pneumococcal carriers
d Weekly family income below the basic needs poverty line (<FJ$175 per week) [28]; data on family income were missing for 269 participants, of whom 38 were PCV10
pneumococcal carriers
e Data on antibiotics use were missing for four participants, of whom one was a PCV10 pneumococcal carrier.
https://doi.org/10.1371/journal.pone.0231041.t003
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interaction between PCV10 vaccination status (P = 0.170) or survey year (P = 0.686) with
ethnicity.
Factors associated with non-PCV10 pneumococcal density
Symptoms of an URTI and young age (infant, toddler, and child participant groups) were posi-
tively associated with median density of non-PCV10 carriage (S3 Table). As with density of
overall and PCV10 pneumococcal carriage, the increase in density of non-PCV10 carriage in
association with survey year was not sustained to the third year post-PCV10 introduction, and
there was no evidence of interaction between PCV10 vaccination status (P = 0.156) survey
year (P = 0.138) with ethnicity.
Discussion
This study provides new findings on the factors associated with overall, PCV10, and non-
PCV10 pneumococcal carriage and density, in the years surrounding PCV10 introduction in a
tropical, upper middle-income country in the Asia-Pacific region.
In this study, iTaukei ethnicity was an independent predictor of carriage (overall, PCV10,
and non-PCV10), after adjustment for PCV10 vaccination status and survey year post-PCV10
introduction. We also checked the potential interaction between ethnicity and other socio-
demographic variables, and found no evidence of interaction. Previously, we found that prior
to PCV10 introduction, iTaukei ethnicity was associated with increased odds of overall pneu-
mococcal carriage in children aged 3–13 months (aOR 2.81 [95% CI 1.76–4.49] P<0.001) [4].
The reason for this association is unknown. Further, we have reported that differences in social
contact patterns by ethnicity partially account for higher prevalence of pneumococci among
iTaukei, compared with FID, but that differences in carriage prevalence are also likely related
to ethnic differences in host or environmental factors [36]. Few studies have described associa-
tions between pneumococcal carriage and indigenous and non-indigenous populations living
in the same area, with similar access to healthcare, and with similar and high PCV coverage
rates. Our findings are consistent with other studies comparing indigenous and non-indige-
nous populations in the same setting. In a pre- and very early post-PCV7 longitudinal study of
280 indigenous and non-indigenous children in remote Australia, who were followed from
birth to 2 years, indigenous status was positively associated with pneumococcal carriage (OR
3.3 [95% CI 2.6–4.2] P<0.001)[37]. In Israel, a longitudinal study of 369 Bedouin and 400 Jew-
ish children enrolled in a trial of PCV7, found Jewish children to have significantly lower odds
of pneumococcal carriage, compared with Bedouin children (aOR 0.14 [0.10–0.21]) [38]. In
contrast, a post-PCV13 cross-sectional study of 352 children aged less than six years in Green-
land, found indigenous ethnicity was not associated with pneumococcal carriage (aOR 0.7
[95% CI 0.3–1.5] P = 0.32) [39]. Likewise, a cross-sectional study in Alaska post-PCV7 involv-
ing 1,275 children aged 3–59 months, found no association between indigenous ethnicity and
overall or PCV7 carriage (OR 1.0 [95% CI 0.8–1.3] and (OR 1.1 [95% CI 0.75–1.6], respec-
tively) [40]. Unlike our study, however, both the Greenland and Alaska studies occurred in
high income settings, which may comparatively reduce the impact of ethnicity based socio-
environmental differences that might be related to pneumococcal carriage. Further, the Green-
land study included few non-Inuit participants, and may have been underpowered for analysis
by ethnicity [39].
Other factors associated with pneumococcal carriage in this study, were largely consistent
with studies from the pre-PCV10 era. For example, we observed young age, residential loca-
tion, living with young children, low family income, and symptoms of URTI to be risk factors
for all types of carriage [4, 8, 12]. Similarly, the majority of studies assessing factors associated
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Table 4. Unadjusted and adjusted differences in medians of overall pneumococcal carriage density in association with participant characteristics in four cross-sec-
tional carriage surveys pre-PCV10 (2012) and annually thereafter (2013–2015) in Fiji (n = 2,441).
Exposure Density of overall pneumococcal carriagea (log10 GE/ml) n,
median / IQR
Unadjusted mean difference (95%
CI)
P-value Adjusted mean difference (95%
CI)
P-value
PCV10 vaccination status 0.408 0.210
Not vaccinated 2026, 4.9 (4.2–5.8) ref Ref
Vaccinatedb 415, 4.9 (4.0–5.7) -0.06 (-0.21, 0.08) -0.13 (-0.35, 0.08)
Survey year 0.004 0.001
Pre-PCV10 (2012) b 707, 4.9 (4.2–5.7) ref ref
1 year post-PCV10
(2013)
655, 5.2 (4.3–5.9) 0.28 (0.13, 0.43) 0.33 (0.18, 0.47)
2 years post-PCV10
(2014)
433, 5.0 (4.1–5.8) 0.11 (-0.06, 0.27) 0.18 (0.00, 0.36)
3 years post-PCV10
(2015)
646, 4.9 (4.0–5.7) 0.00 (-0.15, 0.15) 0.01 (-0.17, 0.18)
Ethnicity 0.012 0.053
Fijian of Indian Descent 495, 4.8 (4.1–5.7) ref ref
iTaukei 1946 5.0 (4.2–5.8) 0.17 (0.04, 0.31) 0.14 (0.00, 0.28)
Participant group 0.003 0.008
Caregivers 193, 4.7 (4.0–5.4) ref ref
Infants (5–8 weeks) 515, 4.9 (4.1–5.7) 0.17 (-0.06, 0.39) 0.17 (-0.06, 0.40)
Toddlers (12–23
months)
845, 5.0 (4.1–5.8) 0.33 (0.11, 0.55) 0.32 (0.08, 0.55)
Children (2–6 years) 888, 5.0 (4.3–5.8) 0.34 (0.12, 0.55) 0.34 (0.12, 0.55)
Residential location 0.612
Rural 1070, 5.0 (4.1–5.7) ref
Urban 1371, 5.0 (4.2–5.7) 0.03 (-0.08, 0.14)
Participant sex 0.597
Male 1166, 5.0 (4.2–5.7) ref
Female 1275, 5.0 (4.2–5.8) 0.03 (-0.08, 0.14)
Number of children < 5
years living in the
household
0.708
Less than two 954, 5.0 (4.2–5.8) ref
Two or more 1487, 5.0 (4.2–5.7) -0.02 (-0.13, 0.09)
Family income levelc 0.943
Not low 801, 5.0 (4.1–5.7) ref
Low 1522, 5.0 (4.2–5.8) 0.00 (-0.11, 0.12)
Symptoms of URTI <0.001 <0.001
Not present 1528, 4.9 (4.1–5.6) ref Ref
Present 913, 5.2 (4.3–5.9) 0.31 (0.19, 0.42) 0.28 (0.16, 0.40)
Household cigarette
smoke
0.540
No exposure 1098, 5.0 (4.1–5.7) ref
Exposure 1343, 5.0 (4.2–5.8) 0.03 (-0.08, 0.15)
Antibiotic use in previous
fortnightd
0..084 0.752
Not used 2324, 5.0 (4.2–5.7) ref ref
Used 115, 5.2 (4.5–5.7) 0.22 (-0.03, 0.48) 0.04 (-0.23, 0.30)
Abbreviations: CI, confidence interval; PCV10, ten-valent pneumococcal conjugate vaccine; URTI, upper respiratory tract infection.
a Density of overall, including non-encapsulated, pneumococci
b Two doses of PCV10 given before the age of 12 months, or one or more doses of PCV10 given after 12 months of age [35]
c Weekly family income below the basic needs poverty line (<FJ$175 per week) [28]; data on family income were missing for 118 pneumococcal carriers
d Data on antibiotic use were missing for two pneumococcal carriers.
https://doi.org/10.1371/journal.pone.0231041.t004
PLOS ONE Factors associated with pneumococcal carriage and density in Fiji
PLOS ONE | https://doi.org/10.1371/journal.pone.0231041 April 1, 2020 10 / 18
with pneumococcal carriage after the introduction of PCV into national immunization sched-
ules have reported age, poverty or proxies of poverty, number of young children living in the
household, and symptoms of URTI as positively associated with pneumococcal carriage [41–
45]. Previous studies have heterogenous findings regarding exposure to cigarette smoke and
recent antibiotic use and their associations with pneumococcal carriage [5, 11, 46–53]. We
found exposure to household cigarette smoke was a risk factor, but only for PCV10 carriage.
However, levels of exposure to cigarette smoke require detailed monitoring, which was not
incorporated in this study. We also found no association between antibiotic use and pneumo-
coccal carriage, which may reflect very low prevalence of recent antibiotic use in our sample.
In this study, PCV10 vaccination status and survey year were protective against overall and
PCV10 carriage, but were not associated with non-PCV10 carriage. We found only three stud-
ies undertaken after PCV was introduced into national immunization programs that assessed
factors associated with pneumococcal carriage, and included PCV vaccination status as a vari-
able [16, 54, 55]. In a cross-sectional study of 361 children under five years of age in Jimma,
Ethiopia, the odds of overall pneumococcal carriage increased in association with having sib-
lings under five years old (aOR 1.80 [95% CI 1.17–2.77] P = 0.008), and malnutrition (aOR
2.07 [95% CI 1.24–3.44] P = 0.005), but PCV vaccination was not associated with a decrease in
carriage (three doses aOR 1.08 [95% CI 0.60–1.89] P = 0.82, one or two doses aOR 1.06 [95%
CI 0.40–2.83] P = 0.90) [54]. This may have been due to serotype replacement and capsular
switching of pneumococci by recombination, such that the immune pressure from PCV
selected for non-vaccine serotypes [54]. However, in a cross-sectional study of 1,668 healthy
children aged 12–23 months in Brazil, the odds of vaccine-type carriage declined in association
with three (aOR 0.073 [95% CI 0.026–0.204] P<0.001) and four (aOR 0.027 [95% CI 0.007–
0.113] P<0.001) doses of PCV10, and increased in association with day care attendance (aOR
2.358 [95% CI 1.455–3.821] P<0.001) and colonization with H. influenzae (aOR 2.454 [95% CI
1.529–3.939] P = 0.0006) [55]. Similarly, in pre and post-PCV13 pneumococcal carriage sur-
veys involving 999 infants aged 5–8 weeks and 1,010 toddlers aged 12–23 months in Lao PDR,
two or three doses of PCV13, compared with zero or one, was protective against PCV13 car-
riage among toddlers (aOR 0.60 [95% CI 0.44–0.83] P = 0.002) [16].
Although our findings are consistent with the Brazilian and Lao PDR studies regarding
PCV being protective against PCV carriage, broader comparisons between these and other
studies is hampered by the heterogeneity of settings, populations sampled, and the factors and
definitions used. For example, in our study participants were community based, healthy, from
four different age groups, did not attend childcare, and we did not include co-colonisers or
malnutrition as exposures. Comparatively, the studies from Ethiopia, Brazil, and Lao PDR
included child and infant participants only, including those attending childcare / school, and
those suffering malnutrition, pneumonia, sinusitis, and otitis media.
Our observations regarding no association between PCV10 and non-PCV10 carriage may
be due a lack of selection pressure towards an overall increase in non-PCV10 carriage early
post-PCV10 introduction, due to serotype replacement occurring only in iTaukei infants and
toddlers, rather than across all participant groups, as described previously [22]. In contrast,
increases in non-vaccine type carriage have been reported following the introduction of PCV7
in England, PCV10 in Kenya, and PCV13 in Malawi and The Gambia [56–59]. However, it
should be noted that the studies from Kenya, England, The Gambia, and Malawi were in vastly
different contexts from our study, one notably in a high-income setting, rendering compari-
sons difficult.
Pneumococcal density has previously been found to be positively associated with microbio-
logically confirmed pneumococcal pneumonia, and could be used to improve estimates of
pneumococcal pneumonia prevalence in childhood pneumonia studies [2].Our study
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contributes to the understanding of factors associated with pneumococcal carriage density.
We found that symptoms of an URTI were associated with increased median density of car-
riage (overall, PCV10, and non-PCV10), consistent with cross-sectional carriage surveys from
Peru, Lao PDR, and Indonesia [9, 11, 13, 16]. We found PCV10 vaccination was not associated
with pneumococcal density, and that although differences in median density of all types of
pneumococci increased one to two years following PCV10 introduction, this was not sustained
into the third year. There are relatively few risk factor studies describing the association
between pneumococcal density and PCV vaccination status. Those that do, have heteroge-
neous findings. A double-blind, randomized controlled trial of PCV13 and Hepatitis A vaccine
(control arm) in adults, using the Experimental Human Pneumococcal Challenge model,
found that pneumococcal density in the PCV13 arm was significantly lower compared with
the control arm (P<0.0001) [60]. In a cluster-randomized trial of PCV7 and Meningococcal C
vaccine (control arm) in rural Gambia, density of PCV7 pneumococcal carriage was lower in
PCV7 villages compared with control arm villages [61]. However, this was not attributed to
PCV7, as density of non-PCV7 carriage also declined in both vaccine and control villages [61].
Similarly, a decline observed in both PCV13 and non-PCV13 pneumococcal density in Laotian
infants and toddlers was attributed to secular trends rather than PCV13 directly [16].
Limitations to our study should be noted. Firstly, because participants were recruited from
Greater Suva and the surrounding areas, generalizability to the wider Fijian population may be
limited. The non-random sampling method may have introduced sample selection bias, such
results may not be generalizable to the Fijian population. However, the purposive quota sam-
pling method rendered the sample representative of the Fijian population with regard to eth-
nicity and residential location, which are associated with pneumococcal carriage [4, 27]. The
cross-sectional nature of this observational study precludes causal, associations from being
drawn between participant characteristics and pneumococcal carriage or densities. Finally, we
did not collect data on co-colonizing bacterial or viral species, and are therefore unable to
investigate the association of such factors with pneumococcal carriage or density, which have
been identified as risk factors in other studies [9–11].
These limitations notwithstanding, this study documents the factors associated with pneu-
mococcal carriage and density post-PCV10 introduction in an upper middle-income country.
Introduction of PCV10 was negatively associated with the odds of overall and PCV10 pneumo-
coccal carriage in Fiji. However, iTaukei ethnicity remains positively associated with pneumo-
coccal carriage in Fiji, despite high and similar PCV10 coverage rates across iTaukei and FID
populations. Further research is warranted regarding the factors underlying the observed eth-
nicity based differences in pneumococcal carriage, and whether the impact of PCV10 on pneu-
mococcal disease incidence differs by ethnicity in Fiji.
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